Skip to main navigation
Skip to search
Skip to main content
Search All UT System Experts
University of Texas Southwestern Medical Center Home
Home
Profiles
Research units
Equipment
Research output
Search by expertise, name or affiliation
Topoisomerase I inhibitors in the combined-modality therapy of lung cancer.
L. Chinsoo Cho,
Hak Choy
Radiation Oncology
Radiation Oncology - Administration
Research output
:
Contribution to journal
›
Review article
›
peer-review
10
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Topoisomerase I inhibitors in the combined-modality therapy of lung cancer.'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Topoisomerase I Inhibitors
100%
Combined Modality Therapy
86%
Irinotecan
65%
Topotecan
57%
Lung Neoplasms
54%
Camptothecin
36%
Type I DNA Topoisomerase
36%
gemcitabine
30%
Head and Neck Neoplasms
27%
Topoisomerase Inhibitors
21%
Taxoids
17%
Non-Small Cell Lung Carcinoma
12%
Therapeutics
11%
Cause of Death
10%
Cell Death
10%
Survival Rate
10%
Radiation
10%
Clinical Trials
9%
Neoplasms
8%
Survival
7%
Enzymes
7%
Lung
7%
Pharmaceutical Preparations
5%